Filter Results

Locations

Study status

(for at least one location)

Gender

Age

Healthy Volunteer

What is this?
A volunteer subject with no known significant health problems who participates in research to test a new drug, device or intervention. These volunteers are recruited to serve as controls for patient groups. Healthy volunteers receive the same test, procedure, or drug the patient group receives.

Study phase

What is this?
During the early phases (phases 1 and 2), researchers assess safety, side effects, optimal dosages and risks/benefits. In the later phase (phase 3), researchers study whether the treatment works better than the current standard therapy. They also compare the safety of the new treatment with that of current treatments. Phase 3 trials include large numbers of people to make sure that the result is valid. There are also less common very early (phase 0) and later (phase 4) phases. Phase 0 trials are small trials that help researchers decide if a new agent should be tested in a phase 1 trial. Phase 4 trials look at long-term safety and effectiveness, after a new treatment has been approved and is on the market.

Search Results 31-40 of 413 for center for individualized medicine

Edit search filters
  1. A Study to Determine the Outcomes of Patients With Localized B Cell Lymphoblastic Lymphoma (B-LLy) When Treated With Standard Risk B-ALL Therapy

    Rochester, MN

  2. Study Evaluating The Safety And Effectiveness Of JCARH125 In Subjects With Relapsed And/or Refractory Multiple Myeloma (EVOLVE)

    Rochester, MN

  3. A Study To Assess The Safety And Antitumor Activity Of Genetically Engineered T Cells In NY-ESO-1 And/or LAGE-1a Positive Solid Tumors

    Jacksonville, FL, Rochester, MN

  4. A Study To Evaluate Effectiveness And Safety Of AL001 In Frontotemporal Dementia

    Rochester, MN

  5. Cisplatin With or Without Veliparib in Treating Patients With Recurrent or Metastatic Triple-Negative and/or BRCA Mutation-Associated Breast Cancer With or Without Brain Metastases

    Rochester, MN, Eau Claire, WI, La Crosse, WI

  6. Long-Term Follow-up Protocol For Participants Treated With Gene-Modified T Cells

    Scottsdale/Phoenix, AZ, Jacksonville, FL, Rochester, MN

  7. Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Brexucabtagene Autoleucel

    Jacksonville, FL, Rochester, MN

  8. A Study to Evaluate UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

    Scottsdale/Phoenix, AZ

  9. Expanded Access Study For The Treatment Of Patients With Commercially Out-of-Specification Axicabtagene Ciloleucel

    Jacksonville, FL, Rochester, MN

  10. A Study To Evaluate MYK-491 To Treat Patients With Primary Dilated Cardiomyopathy (DCM) Due To Genetic Variants

    Rochester, MN

.

Mayo Clinic Footer